ADEL signs $1.04 billion Alzheimer’s licensing deal with Sanofi
In what was a busy day for Sanofi (Euronext: SAN), the French pharma major has entered into a licensing and development collaboration with South Korea’s ADEL Inc for the development and commercialization of ADEL-Y01, a potential first-in-class antibody therapy for Alzheimer's disease and related backup compounds.
The total potential value of the agreement is up to $1.04 billion. ADEL will receive a non-refundable upfront payment of $80 million, and is eligible to receive additional payments contingent upon the achievement of specified development and commercial milestones. Additionally, ADEL is entitled to receive tiered royalties on net sales ranging up to double-digit percentages.
Also today, Sanofi announced an expanded deal with USA-based Dren Bio on autoimmune diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze